[HTML][HTML] Evaluating barriers and facilitators to the uptake of mHealth apps in cancer care using the consolidated framework for implementation research: scoping …
Background: Mobile health (mHealth) solutions have proven to be effective in a wide range
of patient outcomes and have proliferated over time. However, a persistent challenge of …
of patient outcomes and have proliferated over time. However, a persistent challenge of …
Electronic health intervention to manage symptoms of immunotherapy in patients with cancer (SOFIA): Results from a randomized controlled pilot trial
Background For patients receiving immune checkpoint inhibitors, early detection of immune‐
related adverse events (irAEs) is critical for one's safety. To this end, a smartphone app …
related adverse events (irAEs) is critical for one's safety. To this end, a smartphone app …
Content features and its implementation in novel app-based psycho-oncological interventions for cancer survivors: a narrative review
F Springer, A Mehnert-Theuerkauf - Current Opinion in Oncology, 2022 - journals.lww.com
Psycho-oncological apps for cancer survivors target many relevant psychological problem
areas and aim to improve patient empowerment. Available mHealth interventions can …
areas and aim to improve patient empowerment. Available mHealth interventions can …
Association between body mass index and immune-related adverse events (irAEs) among advanced-stage cancer patients receiving immune checkpoint inhibitors: a …
Simple Summary Currently, clinical studies exploring the impact of high body fat on toxicities
after receiving immune checkpoint inhibitors (ICIs) among cancer patients are limited. Here …
after receiving immune checkpoint inhibitors (ICIs) among cancer patients are limited. Here …
Patient-reported outcome (PRO)-based symptom assessment in patients with advanced lung cancer receiving first-line combination immunotherapy: a protocol for a …
Y Deng, H Hu, R Jia, W Dai, D Wang, P Zhang… - BMC Pulmonary …, 2023 - Springer
Background Immunotherapy is currently applied in the first-line treatment regimens for
numerous advanced cancers, especially advanced lung cancer. Immune-related adverse …
numerous advanced cancers, especially advanced lung cancer. Immune-related adverse …